首页> 外文期刊>International archives of allergy and immunology >Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases.
【24h】

Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases.

机译:妊娠对肥大细胞增多症的临床影响:西班牙对肥大细胞增多症网络(REMA)的研究45例。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The impact of pregnancy on mast cell (MC)-related symptoms and newborn outcome in women with mastocytosis is not well described. We report a series of 30 women who had 45 pregnancies. METHODS: Patients completed a specific questionnaire concerning MC mediator release symptoms graded according to their frequency to detect clinical changes occurring during pregestation and pregnancy as well as postpartum. Information about the medications received during pregnancy and labor and about newborn medical complications was also recorded. RESULTS: Worsening of MC-related symptoms during pregnancy was observed in 10 cases (22%); additionally, 1 woman developed skin lesions as a manifestation of indolent systemic mastocytosis (ISM) within the third trimester of pregnancy. Conversely, 15 cases (33%) experienced clinical improvement during pregnancy, with a complete resolution of pregestational symptoms in 7 cases. MC mediator release symptoms intrapartum were observed in 5 cases (11%) without any fatal outcome. Newborn medical complications (e.g. prematurity, low birth weight, and respiratory distress) were detected in 7 infants (16%) who were all successfully managed with conservative measures. One infant developed cutaneous mastocytosis several years after birth. CONCLUSIONS: Mastocytosis has a heterogeneous clinical behavior during pregnancy: the profile of MC-related symptoms remained unchanged in half of the cases, while in the other half pregnant women experienced either an improvement or an exacerbation of the symptoms, with the manifestation of ISM during pregnancy in 1 case. To prevent potential life-threatening MC-related symptoms, adequate prophylactic antimediator therapy intrapartum should be systematically administered. The absence of both maternal and infant severe complications suggests that patients with nonaggressive categories of mastocytosis should not be advised against pregnancy.
机译:背景:妊娠对肥大细胞增多症妇女的肥大细胞(MC)相关症状和新生儿结局的影响尚无很好的描述。我们报告了30例有45例怀孕的妇女。方法:患者完成了一份有关MC介质释放症状的特定调查表,该症状根据其频率分级,以检测孕前,妊娠以及产后发生的临床变化。还记录了有关怀孕和分娩期间所用药物以及新生儿医疗并发症的信息。结果:10例(22%)观察到孕期MC相关症状加重。此外,有1位妇女在妊娠中期出现皮肤病变,表现为惰性全身性肥大细胞增多症(ISM)。相反,有15例(33%)在怀孕期间经历了临床改善,其中7例完全缓解了孕期症状。 5例(11%)观察到产妇MC介质释放症状,无致命后果。在7例(16%)婴儿中发现了新生儿医疗并发症(例如早产,低出生体重和呼吸窘迫),这些婴儿均通过保守措施成功治愈。一名婴儿出生后几年发展为皮肤肥大细胞增多症。结论:肥大细胞增多症在妊娠期间具有不同的临床行为:在一半的病例中,MC相关症状的特征保持不变,而在另一半中,孕妇在症状改善或加重时出现ISM症状。妊娠1例。为防止潜在的威胁生命的MC相关症状,应系统地进行足够的产前预防性中介药治疗。母婴均无严重并发症,提示不建议患有肥大性肥大细胞增多症的患者不要妊娠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号